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Introduction
Pancreatic cancer remains a deadly disease in which the
incidence and mortality are identical. Few patients sur-
vive, and the long-term surgical survivors are prone to
recurrence, even 10–15 years later. The incidence of
pancreatic cancer has remained static for the last decade
with male and female incidence being similar; approxi-
mately 10 new cases occur per 100 000 population per
annum. The recent trend has been for the disease to
occur in older age groups and now in the UK 50%
of patients are over 75 years of age. Risk factors are
few and the aetiology appears multifactorial; smoking
appears the most important, with chronic pancreatitis,
hereditary predisposition, diabetes and carcinogens
being of importance. Approximately 90% of tumours are
ductal carcinomas with the remaining 10% being a wide
range of diﬀerent tumour types with a remarkably
variable prognosis. The importance of defining the his-
tology is probably of greater importance in pancreatic
cancer than in most other tumours. Characteristically,
tumours present late.
Symptoms and signs
The suspicion of pancreatic cancer arises because of
symptoms such as pain, jaundice, weight loss, anorexia
or early satiety. Less common symptoms include venous
thrombosis, diarrhoea, new onset diabetes or acute
pancreatitis. Back pain is ominous and associated with a
shortened survival. Painless jaundice is the most com-
mon presentation in patients with a potentially resect-
able and curable lesion (52% of patients with a
resectable lesion). Pain, however, is the most frequent
symptom and is present in 80% and 85% of patients with
locally unresectable and advanced cancer, respectively.
The combination of pain and jaundice is present in 50%
of patients with a locally unresectable tumour.
In a prospective study of 39 patients with unresectable
pancreatic cancer, 82% had pain at the time of diagnosis,
64% anorexia, 62% early satiety, 54% sleep problems,
and 51% weight loss. Significant correlation has been
found between dyspnoea and length of survival.
Pathology
Currently there are two major classifications; the TNM
created by the UICC and a Japanese system (JPN)
created by the Japan Pancreas Society. UICC is based
on tumour size and the presence or absence of nodal or
remote metastases, whereas the JPN classification has
more criteria; for example, a more detailed evaluation of
the degree of invasion into vessels, retroperitoneum and
nerves. Evaluation of the remote nodal, as well as the
hepatic and peritoneal metastases is more neatly diﬀer-
entiated. For individual tumours, the WHO classifica-
tion[1] groups the exocrine tumours according to their
biological behaviour. The division between benign and
malignant is not sharp, but rather a gradual transition
analogous to some ovarian tumours. The borderline
group, known as ‘tumours of uncertain malignant
potential’ are defined by the grade of dysplasia and their
potential to become malignant. In the 1996 edition of
the classification, a new name ‘intraductal papillary
mucinous tumour’ replaced vague terms such as ‘mucin-
producing tumour’, ‘mucinous duct ectasia’ and ‘solid
pseudopapillary tumour’ (Table 1). Ductal adenocarci-
nomas compose 90% of pancreatic tumours. Sixty-five
per cent of these tumours arise in the head of the
pancreas, 15% originate in the body and tail, and 20%
diﬀusely involve the gland. The tumour infiltrates and
creates a fibrous response such that the extent is diﬃcult
to appreciate and indeed, microscopically, extends
significantly beyond the grossly recognized tumour
mass. At the time of presentation most tumours have
metastasized to the lymph nodes, and later extend to
the liver (80%), peritoneum (60%), lungs and pleura
(50–70%), and the adrenal glands (25%). Most ductal
adenocarcinomas infiltrate the perineural, lymphatic
and vascular channels.
Endocrine pancreatic tumours arise from the diﬀuse
endocrine system (DES), the cells of which share a
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number of antigens with nerve elements, hence the name
‘neuroendocrine’. The importance of these tumours is
that the relatively benign and diﬀerentiated tumours give
rise to systemic endocrine syndromes (insulinoma,
gastrinoma, glucagonoma, VIPoma, PPoma), while the
more malignant and non-hormone-producing tumours
grow slowly and have a longer life-cycle than the ductal
cancer. Similarly, ampullary tumours have diﬀerent
behavioural patterns and present early due to obstruc-
tion of the ampulla of Vater; their prognosis is similar to
colonic tumours. It is important to characterize precisely
the pancreatic tumour in order to define a treatment
plan and consider prognosis.
Diagnosis
The therapeutic advantages of an early, accurate and
precise diagnosis are obvious and indicate the need for
standards for history-taking and physical examination
as well as non-invasive, highly sensitive and specific
methods of investigation. The diagnosis of carcinoma in
the head of the pancreas can be made in 90% of patients
on the basis of clinical presentation. In a study of 356
patients with pancreatobiliary carcinoma, the clinical
and diagnostic tests reviewed showed that percutaneous
transhepatic cholangiography (PTC) and computed
tomography (CT) scanning were associated with the
highest provision of information, but the most cost-
eﬀective investigations were ultrasound and liver func-
tion tests. A software program produced a diagnostic
accuracy of 84%.
The role of investigation is to determine whether or
not a tumour is suitable for resection or palliation. The
objective of palliation, which is the lot of the majority
of patients, is to prolong life by relieving suﬀering,
namely the obstructive jaundice and the luminal
obstruction. Non-operative approaches are the preferred
method. Evidence is not available to suggest that pallia-
tive resection has any advantage over non-operative
palliation. Surgical palliation is reserved for the patient
who is considered operable but at surgery found not to
be so. Thus the surgical view of pancreatic cancer is that
of operating on a suitable patient.
Indications for resection
The ideal tumour is one which is locally confined and
has a good prognosis. The histology is important, but
this can usually be surmised from investigations. The
rare benign and good prognostic non-duct cell carci-
nomas have characteristic radiological features and are
more prevalent in the body and tail of the pancreas than
in the head of the gland. Ampullary tumours are diag-
nosed endoscopically but their extent needs to be
assessed radiologically. Biopsy, which is usually
achieved by percutaneous techniques, is limited to the
patient who is considered inoperable, however, rarely, as
in neuroendocrine tumours, a biopsy is required if the
tumour is submitted for pre-operative chemoradio-
therapy. Indeed, it is recommended that before starting
either chemotherapy or radiotherapy, a biopsy should be
performed.
Operability
For the patient suitable for resection the surgeon needs
to know that the disease is confined to the pancreas and
that a standard resection will encompass the tumour.
The standard resection is a pancreatoduodenectomy
which excises the duodenum, the head of the pancreas
and the lower bile duct. Extended procedures which
involve radical lymphadenectomy have not improved
survival. Incomplete excisions do not improve survival;
it behoves the surgeon to select the patient for
resection in which the tumour is completely excised both
macroscopically and microscopically.
The markers of inoperability are distant metastases,
involved lymph nodes away from the pancreas and
involvement of the portal vein or superior mesenteric
artery. State-of-the-art helical CT scanning, with or
without magnetic resonance imaging (MRI) should
accurately predict operability in 60–70% of patients.
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Laparoscopic examination of the abdominal cavity will,
at most, improve this yield by 10%. The eﬀect of
endoscopic ultrasound, peritoneal washings, bone mar-
row biopsy and PET scanning have yet to be fully
evaluated. It is cost-eﬀective to limit the investigations to
state-of-the-art CT scanning and accept a slightly higher
rate of inoperable cases which can be managed by
surgical palliation.
With selection the surgical outcome should be a
mortality of under 5% and a 5-year survival of 20% for
duct cell carcinomas. The quality of life for patients
undergoing pancreatoduodenectomy is good and their
initial recovery period is no longer than 3 months before
achieving an acceptable normalization of life. Adjuvant
chemotherapy improves survival by 10%. Radio-
therapy does not improve survival and it may even be
harmful.
Conclusion
The surgeons’ view of pancreatic carcinoma is that the
diagnosis should be made early, the investigations
should be undertaken expeditiously and the investiga-
tions limited to helical CT scanning. For those patients
with an inoperable tumour a biopsy is appropriate.
Operative mortality should be low and the quality of life
following recovery from resection good.
Key points
(1) Incidence of disease far more common in the elderly
(2) Histological type of great importance prognostically
(3) Early diagnosis essential
(4) Operability determined by high quality imaging
(5) Resection associated with a <5% mortality and a
20% 5-year survival
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Carcinoma of the pancreas: detection and staging
using CT and MRI
Jay P Heiken
Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, Missouri, USA
Our ability to diagnose pancreatic carcinoma has improved
substantially over the past 20 years, owing to major
advances in pancreatic imaging, including the development
of US, CT and MRI. Despite these advances, however, the
prognosis of patients with pancreatic cancer remains dis-
mal. The overall 5-year survival rate is only 3%[1], although
the 5-year survival rate for patients who undergo pancreatic
resection is reported to be approximately 20%[2–4]. Because
of the very poor prognosis of patients with pancreatic
carcinoma, many physicians take a nihilistic approach to its
diagnosis and staging. It is important to keep in mind,
however, that a large percentage of patients with pancreatic
cancer who undergo laparotomy for possible curative resec-
tion are found to have unresectable disease. Thus, optimi-
zation of pre-operative imaging is important in order to
reduce the percentage of patients who are unnecessarily
subjected to laparotomy.
CT has become established as the primary initial imaging
method for both detection and staging of suspected pancre-
atic carcinoma. Most studies have found that CT is highly
reliable when it demonstrates features indicating that a
tumor is unresectable[5,6]. The positive predictive value
(PPV) of a diagnosis of unresectability with helical CT has
ranged from 92% to 100%[7–11]. Helical CT is less reliable,
however, for predicting that a tumor is resectable
(PPV=76–90%)[7–11]. Nevertheless, this represents a sub-
stantial improvement over prediction of resectability with
conventional CT (PPV=45–72%)[12–14]. Limitations of CT
include: poor ability to demonstrate small hepatic or peri-
toneal metastases; inability to demonstrate microscopic
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